Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting.
Burger EA, Laprise JF, Sy S, Regan MC, Prem K, Jit M, Brisson M, Kim JJ.
Int J Cancer. 2022 May 05. PMID: 35512109
Research Scientists
Emily Annika Burger
Links
Bibliography
Healthcare expenditure of intravitreal anti-vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema.
Hertzberg SN, Moe MC, Jørstad ØK, Petrovski BÉ, Burger E, Petrovski G.
Acta Ophthalmol. 2022 Apr 25. PMID: 35467793
Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
Portnoy A, Pedersen K, Nygård M, Trogstad L, Kim JJ, Burger EA.
Med Decis Making. 2022 Mar 08. 272989X221082683. PMID: 35255741
Impact of Delaying Effective and Cost-Effective Policy Decisions: An Example From Cervical Cancer Prevention in Norway.
Portnoy A, Nygård M, Trogstad L, Kim JJ, Burger EA.
MDM Policy Pract. 2022 Jan-Jun. 7(1):23814683211071093. PMID: 35024449
Potential effectiveness of a therapeutic HPV intervention campaign in Uganda.
Spencer JC, Campos NG, Burger EA, Sy S, Kim JJ.
Int J Cancer. 2022 03 01. 150(5):847-855. PMID: 34741526
Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
Pedersen K, Portnoy A, Sy S, Hansen BT, Tropé A, Kim JJ, Burger EA.
Int J Cancer. 2022 02 01. 150(3):491-501. PMID: 34664271
Cost-effectiveness of nonavalent HPV vaccine in Norway considering current empirical data and validation.
Portnoy A, Pedersen K, Trogstad L, Hansen BT, Feiring B, Laake I, Smith MA, Sy S, Nygård M, Kim JJ, Burger EA.
Prev Med. 2021 09. 150:106688. PMID: 34303489
Retraction: Impact and Cost-effectiveness of Human Papillomavirus Vaccination Campaigns.
Portnoy A, Campos NG, Sy S, Burger EA, Cohen J, Regan C, Kim JJ.
Cancer Epidemiol Biomarkers Prev. 2021 Jun. 30(6):1283. PMID: 34074734
Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.
Smith MA, Burger EA, Castanon A, de Kok IMCM, Hanley SJB, Rebolj M, Hall MT, Jansen EEL, Killen J, O'Farrell X, Kim JJ, Canfell K.
Prev Med. 2021 10. 151:106623. PMID: 34029578
Cervical screening during the COVID-19 pandemic: optimising recovery strategies.
Castanon A, Rebolj M, Burger EA, de Kok IMCM, Smith MA, Hanley SJB, Carozzi FM, Peacock S, O'Mahony JF.
Lancet Public Health. 2021 07. 6(7):e522-e527. PMID: 33939965